Portopulmonary hypertension;Portopulmonale hypertonie

Zeitschrift fur Gastroenterologie

Volumn 43, Issue 7, 2005, Pages 677-685

  Halank, Michael ^a   Miehlke, S ^a   Kolditz, M ^a   Hoeffken, G ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Endothelin; Liver cirrhosis; Portal hypertension; Portopulmonary hypertension; Pulmonary hypertension

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PROSTACYCLIN;

HEPATOPULMONARY SYNDROME; HUMAN; HYPERVOLEMIA; LIVER TRANSPLANTATION; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; MORTALITY; PORTAL HYPERTENSION; PULMONARY HYPERTENSION; REVIEW; SYMPTOMATOLOGY;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; HEPATOPULMONARY SYNDROME; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; ILOPROST; INFUSIONS, INTRAVENOUS; LUNG; PULMONARY WEDGE PRESSURE; SULFONAMIDES; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 23144433098     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-857926     Document Type: Review

References (79)

1. Sood G, Fallon MB, Niwas S et al. Utility of a dyspnea-fatigue index for screening liver transplant candidates for hepatopulmonary syndrome. Hepatology 1998; 28: 2319 A
2. Rolando N, Harvey F, Brahm J et al. Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. Hepatology 1990; 11: 49-53
3. Lazaridis KN, Frank JW, Krowka MJ et al. Hepatic hydrothorax: pathogenesis, diagnosis, and management. Am J Med 1999; 107: 262-267
4. Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. Swiss Med Wkly 2003; 133: 163-169
5. Schenk P, Fuhrmann V, Madl C et al. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut 2002; 51: 853-859
6. Gupta D, Vijaya DR, Gupta R et al. Prevalence of hepatopulmonary syndrome in cirrhosis and extrahepatic portal venous obstruction. Am J Gastroeneterol 2001; 96: 3395-3399
7. Martinez GP, Barbara JA, Visa J et al. Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol 2001; 34: 651-657
8. Lange PA, Stoller JK. The hepatopulmonary syndrome. Ann Intern Med 1995; 122: 521-529
9. Bauditz J, Schmidt H. Klinische Signifikanz des hepatopulmonalen Syndroms. Z Gastroenterol 2004; 42: 539-542
10. Rolla G, Brussino L, Colagrande P et al. Exhaled nitric oxide and impaired oxygenation in cirrhotic patients before and after liver transplantation. Ann Intern Med 1998; 129: 375-378
11. Rodriguez-Roisin R, Krowka MJ, Herve P et al. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004; 24: 861-880
12. Mantz FA Jr, Craige E. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. AMA Arch Pathol 1951; 52: 91-97
13. Krowka MJ. Hepatopulmonary syndrome versus portopulmonary hypertension: distinctions and dilemmas. Hepatology 1997; 25: 1282-1284
14. Rich S. Primary pulmonary hypertension: executive summary from the world symposium on primary pulmonary hypertension 1998. Geneva: World Health Organization, 1998
15. McDonnel PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983; 127: 437-441
16. Cheng E, Woehlck H. Pulmonary artery hypertension complicating anesthesia for liver transplantation. Anesthesiology 1992; 77: 389-392
17. Castro M, Krowka MJ, Schroeder R et al. Frequency and clinical implications of increased pulmonary pressures in liver transplant patients. Mayo Clin Proc 1996; 71: 543-551
18. Benjaminov FS, Prentice M, Sniderman KW et al. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 2003; 52: 1355-1362
19. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117
20. Naeije R. Pulmonary Circulation. In: Gibson CJ, Geddes DM, Costabel U, Sterk PJ, Corris B (eds). Respiratory Medicine. Third edition. London: Saunders, 2003: Vol. 1: 147-157
21. Krowka MJ. Hepatopulmonary syndromes. Gut 2000; 46: 1-4
22. Mandell MS. Critical care issues: portopulmonary hypertension. Liver Transpl 2000; 6 (4 Suppl 1): S36-43
23. Kuo PC, Plotkin JS, Johnson LB et al. Distinctive clinical features of portopulmonary hypertension. Chest 1997; 112: 980-986
24. Colle IO, Moreau R, Godinho E et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37: 401-409
25. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363: 1461-1468
26. Hadengue A, Benhayoun MK, Lebrec D et al. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100: 520-528
27. Auletta M, Oliviero U, Iasiuolo L et al. Pulmonary hypertension associated with liver cirrhosis: an echocardiographic study. Angiology 2000; 51: 1013-1020
28. Molden D, Abraham JL. Pulmonary hypertension. Its association with hepatic cirrhosis and iron accumulation. Arch Pathol Lab Med 1982; 106: 328-331
29. Shah V, Toruner M, Haddad F et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999; 117: 1222-1228
30. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: Implications for regulation of portal pressure and resistance. Hepatology 1996; 24: 233-240
31. Kamath PS, Tyce GM, Miller VM et al. Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension. Hepatology 1999; 30: 401-407
32. Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996; 17: 17-33
33. Edwards BS, Weir EK, Edwards WD et al. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 1987; 10: 1233-1238
34. Soh H, Hasegawa T, Sasaki T et al. Pulmonary hypertension associated with postoperative biliary atresia: report of two cases. J Pediatr Surg 1999; 34: 1779-1781
35. Tokiwa K, Iwai N, Nakamura K et al. Pulmonary hypertension as a fatal complication of extrahepatic portal hypertension. Eur J Pediatr Surg 1993; 3: 373-375
36. BK, Pal A, Santra A et al. Primary pulmonary hypertension in non-cirrhotic portal fibrosis. Indian J Gastroenterol 1997; 16: 85-87
37. Huonker M, Schumacher YO, Ochs A et al. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999; 44: 743-748
38. Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther 2001; 89: 221-231
39. Tuder RM, Cool CD, Yeager M et al. The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 2001; 22: 405-418
40. Gerbes AL, Moller S, Gulberg V et al. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: a role of splanchnic and renal passage and liver function. Hepatology 1995; 21: 735-739
41. Nagasue N, Dahr DK, Yamanoi A et al. Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis. Hepatology 2000; 31: 1107-1114
42. Halank M, Miehlke S, Höffken G et al. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation 2004; 77: 1775-1776
43. Hinterhuber L, Graziadei IW, Kahler CM et al. Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol 2004; 2: 1039-1042
44. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991; 17: 492-498
45. Salvi SS. Alpha 1-adrenergic hypothesis for pulmonary hypertension. Chest 1999; 115: 1708-1719
46. Cella G, Belleto F, Tona F et al. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest 2001; 120: 1226-1228
47. Tuder RM, Cool CD, Geraci MW et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-1932
48. Herve P, Lebrec D, Brenot F et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998; 11: 1153-1166
49. Halank M, Marx C, Hoeffken G. Long term survival in primary pulmonary hypertension. Heart 2004; 90: e40
50. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81
51. Fuster V, Steele PM, Edwards WD et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-587
52. Krowka MJ, Frantz RP, McGoon MD et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30: 641-648
53. Kuo PC, Johnson LB, Plotkin JS et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63: 604-606
54. Plotkin JS, Kuo PC, Rubin LJ et al. Succesfull use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998; 65: 457-459
55. McLaughlin W, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482
56. Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788
57. Schroeder RA, Rafii AA, Plotkin JS et al. Use of aerosolized inhaled epoprostenol in the treatment of portopulmonary hypertension. Transplantation 2000; 70: 548-550
58. Halank M, Marx C, Usicenko S et al. Inhaled Iloprost for patients with portopulmonary hypertension. Am J Respir Crit Care Med 2003; 167: A277
59. Halank M, Marx C, Miehlke S et al. Use of aerosolized inhaled iloprost in the treatment of portopulmonary hypertension. J Gastroenterol 2004; 39: 1222-1223
60. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123
61. Rubin LJ, Badesch DB, Barst R et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903
62. Hoeper MM, Halank M, Marx C et al. Bosentan therapy for portopulmonary hypertension. Eur Resp J 2005 (in press)
63. Sastry BK, Narasimhan C, Reddy NK et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomised, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43: 1149-1153
64. Olschewski H, Ghofrani A, Wiedemann R et al. Pulmonaler Hochdruck. Internist 2002; 43: 1498-1509
65. Boot H, Visser FC, Thijs JC et al. Pulmonary hypertension complicating portal hypertension: a case report with suggestions for different therapeutic approach. Eur Heart J 1987; 8: 656-660
66. Raffy O, Sleiman C, Vachiery F et al. Refractory hypoxemia during liver cirrhosis. Hepatopulmonary syndrome or "primary" pulmonary hypertension? Am J Respir Crit Care Med 1996; 153: 1169-1171
67. Ribas J, Angrill J, Barbera JA et al. Isosorbide-5-mononitrate in the treatment of pulmonary hypertension associated with portal hypertension. Eur Respir J 1999; 13: 210-212
68. Tan HP, Markowitz JS, Montgomery RA et al. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. Liver Transpl 2001; 7: 745-749
69. Levy MT, Torzillo P, Bookallil M et al. Case report: delayed resolution of severe pulmonary hypertension after isolated liver transplantation in a patient with cirrhosis. J Gastroenterol Hepatol 1996; 11: 734-737
70. Schott R, Chaouat A, Launoy A et al. Improvement of pulmonary hypertension after liver transplantation. Chest 1999; 115: 1748-1749
71. Koneru B, Ahmed S, Weisse AB et al. Resolution of pulmonary hypertension of cirrhosis after liver transplantation. Transplantation 1994; 58: 1133-1135
72. Taura P, Garcia-Valdecasas JC, Beltran J et al. Moderate primary pulmonary hypertension in patients undergoing liver transplantation. Anesth Analg 1996; 83: 675-680
73. Castro M, Krowka MJ, Schroeder DR et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996; 71: 543-551
74. Ramsay MA, Simpson BR, Nguyen AT et al. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997; 3: 494-500
75. Krowka MJ, Plevak DJ, Findlay JY et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6: 443-450
76. Pirenne J, Verleden G, Nevens F et al. Combined liver and (heart-) lung transplantation in liver transplant candidates with refractory portopulmonary hypertension. Transplantation 2002; 73: 140-142
77. Dennis CM, McNeil KD, Dunning J et al. Heart-lung-liver transplantation. J Heart Lung Transplant 1996; 15: 536-538
78. Azoulay D, Castaing Y, Dennison A et al. Transjugular intrahepatic portosystemic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient. Hepatology 1994; 19: 129-132
79. Van der Linden P, Le Moine O, Ghysels M et al. Pulmonary hypertension after transjugular intrahepatic portosystemic shunt: effects on right ventricular function. Hepatology 1996; 23: 982-987